UA41315C2 - Вакцинна композиція проти респіраторно-синцитіального вірусу, спосіб стимулювання імунної системи індивідуума для індукції захисту проти респіраторно-синцитіального вірусу - Google Patents

Вакцинна композиція проти респіраторно-синцитіального вірусу, спосіб стимулювання імунної системи індивідуума для індукції захисту проти респіраторно-синцитіального вірусу

Info

Publication number
UA41315C2
UA41315C2 UA94105948A UA94105948A UA41315C2 UA 41315 C2 UA41315 C2 UA 41315C2 UA 94105948 A UA94105948 A UA 94105948A UA 94105948 A UA94105948 A UA 94105948A UA 41315 C2 UA41315 C2 UA 41315C2
Authority
UA
Ukraine
Prior art keywords
attenuated
virus
individual
immune system
stimulation
Prior art date
Application number
UA94105948A
Other languages
English (en)
Inventor
Брайєн Роберт Мьорфі
Роберт Мєрріт Ченок
Джеймс Ерл Крауе
Марк КОННОРС
Куо-хом Лі Хсу
Алан Роберт Девіс
Майкл Девід Любек
Бернард Х'ю Селлінг
Original Assignee
Амерікан Хоум Продактс Корпорейшн
Американ Хоум Продактс Корпорейшн
Сполучені Штати Америки, Що Представлені Департаментом Охорони Здоров'Я
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амерікан Хоум Продактс Корпорейшн, Американ Хоум Продактс Корпорейшн, Сполучені Штати Америки, Що Представлені Департаментом Охорони Здоров'Я filed Critical Амерікан Хоум Продактс Корпорейшн
Publication of UA41315C2 publication Critical patent/UA41315C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Vertical, Hearth, Or Arc Furnaces (AREA)

Abstract

Даний винахід стосується металургії. Пропонується конструкція шахти доменної печі, що містить кожух, який у охолоджуваній частині шахти захищений вогнетривкою футерівкою, а у не охолоджуваній частині шахти футерований металевими не охолоджуваними плитами. Обернений до середини печі бік плит має заглиблення, заповнені вогнетривким матеріалом. Така конструкція шахти дає можливість зберегти профіль доменної печі протягом кампанії, заощадити вогнетривкі матеріали та запобігти продувам кожуху у не охолоджуваній частині шахти.
UA94105948A 1992-04-21 1993-04-20 Вакцинна композиція проти респіраторно-синцитіального вірусу, спосіб стимулювання імунної системи індивідуума для індукції захисту проти респіраторно-синцитіального вірусу UA41315C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87274692A 1992-04-21 1992-04-21
US3994593A 1993-04-09 1993-04-09
PCT/US1993/003670 WO1993021310A1 (en) 1992-04-21 1993-04-20 Attenuated respiratory syncytial virus vaccine compositions

Publications (1)

Publication Number Publication Date
UA41315C2 true UA41315C2 (uk) 2001-09-17

Family

ID=26716607

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94105948A UA41315C2 (uk) 1992-04-21 1993-04-20 Вакцинна композиція проти респіраторно-синцитіального вірусу, спосіб стимулювання імунної системи індивідуума для індукції захисту проти респіраторно-синцитіального вірусу

Country Status (18)

Country Link
US (3) US5922326A (uk)
EP (1) EP0640128B1 (uk)
JP (1) JP3883202B2 (uk)
KR (1) KR100257171B1 (uk)
AT (1) ATE181359T1 (uk)
AU (1) AU683840B2 (uk)
CA (1) CA2118509C (uk)
DE (1) DE69325370T2 (uk)
DK (1) DK0640128T3 (uk)
ES (1) ES2132233T3 (uk)
GR (1) GR3031208T3 (uk)
HU (1) HU220189B (uk)
IL (1) IL105456A (uk)
MX (1) MX9302278A (uk)
NZ (1) NZ252857A (uk)
RU (1) RU2139729C1 (uk)
UA (1) UA41315C2 (uk)
WO (1) WO1993021310A1 (uk)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
TW275632B (uk) * 1992-04-21 1996-05-11 American Cyanamid Co
DE69409243T2 (de) 1993-08-06 1998-08-06 Connaught Lab Inaktivierte respiratorische synzytial-virus-impfstoffe
US7223410B1 (en) 1994-08-05 2007-05-29 Sanofi Pasteur Limited Inactivated respiratory syncytial viral vaccines
WO1996010400A1 (en) * 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
US6083925A (en) 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US20050287540A1 (en) * 1995-09-27 2005-12-29 Murphy Brian R Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
JPH11512609A (ja) 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
AU2438597A (en) * 1996-04-04 1997-10-29 Regents Of The University Of Michigan, The Attenuated respiratory syncytial virus
US6077514A (en) * 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
ATE234631T1 (de) * 1996-07-12 2003-04-15 Aventis Pasteur Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
EP2112220A3 (en) * 1996-07-15 2010-01-06 The Government of the United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
AU4427897A (en) * 1996-09-27 1998-04-17 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
FR2764903A1 (fr) * 1997-06-23 1998-12-24 Pasteur Institut Detection des infections par des paramyxovirus (virus respiratoire syncitial et virus parainfluenza) utilisant des polynucleotides codant de la proteine l
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US7662397B2 (en) 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6482414B1 (en) 1998-08-13 2002-11-19 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6579528B1 (en) 1998-08-13 2003-06-17 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
WO2000061611A2 (en) 1999-04-13 2000-10-19 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7820182B2 (en) * 1999-07-09 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
EP1287152B1 (en) 1999-07-09 2008-12-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Human-bovine chimeric respiratory syncytial virus vaccines
CA2403979A1 (en) 2000-04-03 2001-10-11 The University Of Pittsburgh Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
KR20040071678A (ko) * 2001-09-28 2004-08-12 유니버시티 오브 사우스 플로리다 Ｒｓｖ 유전자 발현 백신
WO2003091401A2 (en) 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1572108A4 (en) * 2002-09-27 2008-09-17 Medimmune Vaccines Inc FUNCTIONAL MUTATIONS OF RSV (RESPIRATORY SYNCYTIAL VIRUS)
CA2518924C (en) * 2003-03-18 2016-06-07 Wyeth Holdings Corporation Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv
ATE469170T1 (de) * 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
ES2345492T3 (es) 2003-12-23 2010-09-24 Medimmune, Llc Sistema multiplasmido para la produccion del virus de la gripe.
WO2005116260A2 (en) * 2004-05-25 2005-12-08 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
EP2049662A4 (en) * 2006-07-21 2009-12-30 Medimmune Llc METHODS AND COMPOSITIONS FOR INCREASING REPLICATION CAPACITY OF A FLU VIRUS
CA2659267C (en) * 2006-08-09 2016-12-13 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
JP5666905B2 (ja) * 2007-06-18 2015-02-12 メディミューン，エルエルシー ヘマグルチニンポリペプチド中に変化を有するインフルエンザｂウイルス
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
SG192501A1 (en) 2008-07-11 2013-08-30 Medimmune Llc Influenza hemagglutinin and neuraminidase variants
WO2010093537A2 (en) * 2009-02-12 2010-08-19 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
GB201003630D0 (en) 2010-03-04 2010-04-21 Novartis Ag Avian rotavirus
SG11201401137TA (en) 2011-10-07 2014-07-30 Medimmune Llc Influenza hemagglutinin variants
EP3875112A1 (en) 2012-04-13 2021-09-08 The United States of America, as Represented By the Secretary, Department of Health and Human Services Genetically stable live attenuated respiratory syncytial virus vaccine and its production
CN105189756B (zh) 2013-03-14 2021-06-11 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
CA2902560A1 (en) * 2013-03-14 2014-09-25 President And Fellows Of Harvard College Nanoparticle-based compositions
US11235050B2 (en) 2015-10-29 2022-02-01 Emory University Chimeric RSV, immunogenic compositions, and methods of use
RU2746280C1 (ru) * 2020-08-03 2021-04-12 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) Штамм респираторно-синцитиального вируса RSV/Novosibirsk/66Hl/2018 для использования в диагностике респираторно-синцитиальной вирусной инфекции и исследования эффективности противовирусных препаратов in vitro

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
US5250298A (en) * 1988-10-07 1993-10-05 University Of Delaware Live attenuated newcastle disease virus vaccines and preparation thereof

Also Published As

Publication number Publication date
JPH07505891A (ja) 1995-06-29
KR100257171B1 (ko) 2000-05-15
EP0640128B1 (en) 1999-06-16
RU2139729C1 (ru) 1999-10-20
CA2118509A1 (en) 1993-10-28
AU4290793A (en) 1993-11-18
US5882651A (en) 1999-03-16
MX9302278A (es) 1994-07-29
HUT69992A (en) 1995-09-28
KR950701382A (ko) 1995-03-23
US5922326A (en) 1999-07-13
EP0640128A1 (en) 1995-03-01
DE69325370T2 (de) 1999-10-14
DK0640128T3 (da) 1999-11-22
WO1993021310A1 (en) 1993-10-28
IL105456A0 (en) 1993-08-18
ATE181359T1 (de) 1999-07-15
DE69325370D1 (de) 1999-07-22
NZ252857A (en) 1997-06-24
GR3031208T3 (en) 1999-12-31
HU220189B (hu) 2001-11-28
IL105456A (en) 1996-12-05
US6284254B1 (en) 2001-09-04
HU9403023D0 (en) 1994-12-28
RU94045898A (ru) 1996-09-20
ES2132233T3 (es) 1999-08-16
JP3883202B2 (ja) 2007-02-21
AU683840B2 (en) 1997-11-27
CA2118509C (en) 2009-05-19

Similar Documents

Publication Publication Date Title
UA41315C2 (uk) Вакцинна композиція проти респіраторно-синцитіального вірусу, спосіб стимулювання імунної системи індивідуума для індукції захисту проти респіраторно-синцитіального вірусу
CA2339089A1 (en) Cold-adapted equine influenza viruses
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
BRPI9710363B1 (pt) partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso.
BG100960A (en) Dosage forms for controlled release of azitromycin
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
MY109143A (en) Sulfonamido-and sulfonamidocarbonylpyridine 2-carboxamides and their pyridine-n-oxides, process for their preparation and their use as pharmaceuticals
HUP9900061A1 (hu) Alumínium-foszfátra adszorbeált konjugált poliszacharid antigént tartalmazó vakcinakompozíciók
MX9604378A (es) Amidas de acido quinolin-2-carboxilico sustituidas, su preparacion y su empleo como medicamentos, asi como productos intermedios.
UA39166C2 (uk) Похідні n-гідроксисечовини, що є інгібіторами ліпоксигенази у ссавців, спосіб їх одержання і спосіб інгібування ліпоксигенази у ссавців
GB9306731D0 (en) Vaccines
ZA89447B (en) Composition and method for protecting against diseases caused by microorganisms
PT789590E (pt) Imunopotenciacao induzida por quitosano
DK0739205T3 (da) Anvendelse af N-alkylderivater af 1,5-didesoxy-1,5-imino-D-glucitol til behandling af hepatitis-B-virusinfektioner
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
WO2000057908A3 (en) Attenuated dengue-1 virus vaccine
MXPA02007403A (es) Derivados de pirrol, sustituidos con 4-piridilo y 2,4-pirimidinilo, y su uso en farmacia.
CA2222482A1 (en) Non-virulent mycoplasma synoviae and vaccine thereof
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
CA2122604A1 (en) Uses of aloe products, e.g. acemannan, in the treatment of diseases requiring intervention of the immune system for cure
IL117083A (en) Pyridine and pyridazine derivatives processes for the production thereof and pharmaceutical compositions containing these compounds
WO2003006645A3 (en) Method and composition for inhibiting heparanase activity
IL124354A0 (en) Hemoregulatory compounds